Forest Labs Sues Sigmapharm To Halt Generic Antipsychotic

Law360, New York (September 4, 2014, 6:18 PM EDT) -- Forest Laboratories LLC sued Sigmapharm Laboratories LLC in Delaware federal court Wednesday over the generic-drug maker's plan to sell a version of Forest's schizophrenia and bipolar treatment drug Saphris.

The suit claims Sigmapharm infringed two patents related to the manufacture of Saphris when it filed an abbreviated new drug application with the U.S. Food and Drug Administration to market a generic version of the antipsychotic drug, which contains the active ingredient asenapine maleate. 

"Sigmapharm infringed one or more claims of the [Forest patents], in violation of...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.